Life Sciences Archives - Page 14 of 21 - Becker's Hospital Review

Gilead scoops drugmaker for $4.3B | 6 Ozempic updates | UT Southwestern, Pfizer partner | 55 best hospitals to work for: Forbes | FDA clears metastatic pancreatic cancer drug

February 14, 2024 BHR Newsletter 1. Gilead scoops drugmaker for $4.3B Full story 2. Best large, midsize health system employers: Forbes Full story 3. 6 Ozempic updates Full story 4. MedStar overhauled its scheduling strategy for better efficiency + provider…

Biogen pulls Aduhelm | Amazon cuts healthcare jobs | 2 cancer drug injectables go into shortage | 5 Ozempic updates | 6 cancer vaccines showing promise

February 7, 2024 BHR Newsletter 1. Biogen abandons controversial Alzheimer's drug Aduhelm Full story 2. Amazon cuts jobs in healthcare divisions Full story 3. 2 more cancer drug injectables fall into shortage Full story 4. Hospitals ahead of the staffing…

Paxlovid emergency use to end | Drugmakers look to class of cancer drugs for growth | Contaminated medical products tied to cases of early Alzheimer's | Gene therapy allows boy to hear | 9 drugs now in shortage

January 31, 2024 BHR Newsletter 1. FDA sets end date for Paxlovid emergency use Full story 2. Contaminated medical products tied to cases of early Alzheimer's Full story 3. Drugmakers turn to class of cancer drugs to fuel growth in…

FDA finds deficiencies at Eli Lilly plant | Ozempic, Mounjaro get pricier | Drug cost trends in 2024 are 'nearly unprecedented' | Best, worst states to retire | FDA clears CRISPR therapy for 2nd disease

January 24, 2024 BHR Newsletter 1. FDA finds deficiencies at Eli Lilly plant: Reuters Full story 2. The best, worst states to retire Full story 3. Ozempic, Mounjaro become pricier Full story 4. The call center is going out of…

Drugmaker halts study after 2 unrelated deaths | Developing a staph vaccine when 'the rules are different' | Eli Lilly weight-loss drug platform draws concern | 5 new drug shortages

January 17, 2024 BHR Newsletter 1. How to develop a staph vaccine when 'the rules are different' Full story 2. New cancer diagnoses set to hit a new high in 2024: American Cancer Society Full story 3. Drugmaker halts study…

J&J to buy Ambrx for $2B | Eli Lilly to sell weight loss drugs directly to consumers | Pfizer to lay off 285 in NY | Best healthcare jobs in 2024 | 4 Ozempic updates

January 10, 2024 BHR Newsletter 1. Johnson & Johnson to buy Ambrx in $2B deal Full story 2. Best healthcare jobs in 2024: US News Full story 3. Eli Lilly to sell weight loss drugs directly to consumers; warns against…

Goldman Sachs closes on $650M life sciences investment fund | Bristol Myers to buy cancer therapy co. for $4B | FDA warns of infection risk over fake Ozempic | Verily's CMO steps down

January 3, 2024 BHR Newsletter 1. Goldman Sachs closes $650M healthcare investment fund to target life sciences Full story 2. Michael Dowling: The most pressing question to start the year Full story 3. Bristol Myers to buy cancer therapy company…

CareFirst sues J&J | Biotech co. lays off 15% of staff | AstraZeneca to buy vaccine co. for $1.1B | Bristol Myers scraps cancer drug trial | 13 of 20 most popular drugs in shortage

December 20, 2023 BHR Newsletter 1. CareFirst sues J&J over alleged anticompetitive biosimilar tactics Full story 2. CAOs: A growing C-suite fixture Full story 3. Biotech company lays off 15% of staff Full story 4. 2 hospitals are transforming care…

Biotech CEO pleads guilty to fraud scheme | US' 1st CRISPR gene therapy to treat sickle cell approved | Moderna exec steps down | Eli Lilly obesity drug hits shelves | Pfizer donates rights to cancer drug

December 13, 2023 BHR Newsletter 1. Biotech CEO pleads guilty to fraud scheme Full story 2. The layoff runway lengthens Full story 3. FDA approves nation's 1st CRISPR gene therapy to treat sickle cell disease: Experts react Full story 4.…

3 patients die in drug trial | Intermountain's biotech spinoff snags $10M | Pfizer exits BIO | The Mark Cuban effect on drug pricing | Eli Lilly blood cancer drug gains approval

December 6, 2023 BHR Newsletter 1. Intermountain's biotech spinoff raises $10M Full story 2. 15 top health systems, per Fortune + Premier Full story 3. 3 patients die in cancer drug trial Full story 4. Virtual nursing — why and…